IMatinib for PAin in Chronic Treatment of Sickle Cell Anemia (IMPACT SCA): A Pilot Study of Imatinib in Patients with Sickle Cell Anemia and Recurrent Vaso-occlusive Pain
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Sickle Cell Disease | Sickle Cell Anemia
Age: Between 18 - 30 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required